HF
GNMK

HRT Financial’s GenMark Diagnostics, Inc GNMK Stock Holding History

HRT Financial’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,437
Closed -$219K – 2763
2020
Q3 		$219K Buy
+15,437
New +$236K 0.01% 1319

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HRT Financial's GNMK Position: Q4 2020 in Review

HRT Financial sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 15,437 shares — an estimated $219K sold.

HRT Financial first reported a position in GNMK in Q3 2020 and held it in 1 quarter. The position peaked at $219K in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • HRT Financial reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • HRT Financial sold 15,437 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $219K.
  • HRT Financial first reported a position in GenMark Diagnostics, Inc in Q3 2020 and held it in 1 quarter.
  • HRT Financial's GenMark Diagnostics, Inc position peaked at $219K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on HRT Financial's 13F filing for Q4 2020, filed 16 Feb 2021.